Our data thus imply that DR protected against proteotoxic phenotypes in non-neuronal tissues (tau-induced lifespan shortening), but not against neuron-specific abnormalities (Aβ42-induced lifespan shortening; Aβ42 or tau-induced climbing and neuronal activity defects) in response to AD pathologies. This evidence concerns the gene MAPT and Alzheimer disease.